Guggenheim raised the firm’s price target on Immunome (IMNM) to $35 from $25 and keeps a Buy rating on the shares after the company reported positive top-line Phase 3 trial results for varegacestat. The firm believes approval likelihood is high and that varegacestat is well-positioned to capture the majority share in the a potential $1B-$2B DT market in the U.S.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- 3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
- Immunome offers to sell $400M in common stock
- Immunome’s Promising Outlook: Buy Rating Affirmed on Varegacestat’s Phase 3 Success and Strong Management
- Immunome price target raised to $40 from $38 at Leerink
- Midday Fly By: Intel eyes SambaNova, Cencora to acquire OneOncology